Clinical Trial Update: OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial [Phase 2]

View source ↗

Summary

A Phase 2 randomized factorial trial to optimize antiviral therapy in immunocompromised COVID-19 patients. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: COVID-19, Immunodeficiency | Phase 2 | Status: RECRUITING